ARST1431 - A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

Is this Study for You?

Let's Get Started!

Details
Age

Child to Adult

Type of Study

Treatment

Locations

Childrens Hospital Colorado

Principal Investigator
Photograph of Timothy Garrington,  MD

Timothy Garrington, MD

Study ID

Protocol Number: 17-1992

More information available at ClinicalTrials.gov: NCT02567435

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers